TWAICE
2.9.2021 15:02:11 CEST | Business Wire | Press release
Battery analytics software expert TWAICE today announced a collaboration with Analog Devices, Inc., a global semiconductor and system solutions company, to tackle the challenges of battery lifecycle optimization. The combination of Analog Devices’ sensor technology and wireless connectivity with TWAICE’s battery analytics software will benefit customers in the mobility and energy sectors. The alliance will be instrumental in significantly reducing warranty risks and recalls, optimizing battery life, and enhancing battery value.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210902005016/en/
Analog Devices is a global leader in battery management systems, and high-performance analog, mixed-signal, and digital signal processing solutions. The collaboration with the software company TWAICE, whose platform provides end-to-end battery analytics solutions, will enable the optimization of the entire battery lifecycle.
Mobility is at an inflection point, with electrified powertrains replacing combustion engines. Battery reliability and economics are critical in the widespread deployment of renewable energies and electric vehicles. Battery performance and lifespan play a key role in the sustainability of solutions they are deployed in, yet the assessment thereof is often challenging. “Precision data combined with advanced predictive battery analytics will shed light into the darkness, which is crucial in unlocking as yet undiscovered potential along the entire value chain," said Dr. Stephan Rohr, Co-CEO of TWAICE.
“The battery is the energy source for every electric vehicle, and it is also a valuable asset,” said Patrick Morgan, Vice President of Automotive at Analog Devices. “Together with TWAICE, we are delivering innovative holistic solutions across battery lifetimes that create significant value for our customers and support a circular economy.”
The goal of the collaboration is to provide a holistic lifecycle solution for automakers with integrated hardware and software. Accurate battery measurements provided through a wireless battery management system form the basis. Analog Devices’ sensor technology provides data, and a quality thereof previously unavailable. TWAICE can generate crucial insights into the battery performance desired by companies around the globe. The resulting forecasts enable qualified statements at any point in the battery lifecycle regarding its value and usability.
About Analog Devices Inc.
Analog Devices (ADI), headquartered in Norwood, Massachusetts, is a global leader in the design, manufacture and marketing of a broad portfolio of high-performance analog, mixed-signal, DSP circuits and microchips used in virtually all types of electronic devices. With over 55 years of market experience, 16,000 employees worldwide today, over 4,700 patents and 125,000 customers in instrumentation, automation, communications, healthcare, automotive and numerous other industries, Analog Devices is dedicated to solving technical challenges associated with signal processing in electronic devices. More at www.analog.com .
About TWAICE
TWAICE provides predictive analytics software that optimizes both the development and operation of lithium-ion batteries. As the leading provider of battery analytics software to global electric vehicle and energy companies, TWAICE increases the longevity, efficiency and sustainability of products that drive tomorrow's economy. More at www.twaice.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210902005016/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom